- Trials with a EudraCT protocol (131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
131 result(s) found for: Monocytes.
Displaying page 5 of 7.
EudraCT Number: 2019-003567-21 | Sponsor Protocol Number: CHDR1912 | Start Date*: 2019-12-04 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, evaluator-blind, vehicle controlled, parallel group study to explore the effects of the anti-inflammatory drug prednisolone in a TLR4 and TLR7 challenge model in healthy volunteers | |||||||||||||
Medical condition: None | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003642-17 | Sponsor Protocol Number: OFM_DUPI_01 | Start Date*: 2018-11-23 |
Sponsor Name:Medical University Graz | ||
Full Title: AN EXPLORATORY STUDY TO INVESTIGATE THE BIOAVAILABILITY AND PHARMACODYNAMICS OF DUPILUMAB IN DERMAL INTERSTITIAL FLUID OF ATOPIC DER-MATITIS PATIENTS | ||
Medical condition: Atopic Dermatitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001390-76 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie... | |||||||||||||
Medical condition: Covid-19 coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002612-31 | Sponsor Protocol Number: MANTICO | Start Date*: 2021-05-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001976-40 | Sponsor Protocol Number: IIV-479 | Start Date*: 2021-05-20 |
Sponsor Name:National Institute for Public Health and the Environment | ||
Full Title: Monitoring immunogenicity of SARS-Cov-2 vaccination in Dutch middle-aged and older individuals (participating in the Doetinchem Cohort Study) | ||
Medical condition: SARS-CoV-19, frailty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000836-24 | Sponsor Protocol Number: IIV-406 | Start Date*: 2019-06-19 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. | ||
Medical condition: Healthy volunteers above 25 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003237-11 | Sponsor Protocol Number: TMP-2005-2020-36 | Start Date*: 2021-11-11 | ||||||||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Institute for translationale Medicine and Pharmacology ITMP | ||||||||||||||||||
Full Title: Effect of Bronchipret on antiviral immune response in patients with mild COVID-19 (BroVID) | ||||||||||||||||||
Medical condition: Adult patients suffering from mild COVID-19 with cough and at least one other symptoms will be recruited for this study. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-005028-40 | Sponsor Protocol Number: MOLTO | Start Date*: 2019-08-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL | |||||||||||||
Medical condition: Richter syndrome of chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004452-15 | Sponsor Protocol Number: ACCESS | Start Date*: 2021-01-14 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: A RANDOMIZED CLINICAL TRIAL OF ORAL CLARITHROMYCIN IN COMMUNITY-ACQUIRED PNEUMONIA TO ATTENUATE INFLAMMATORY RESPONSES AND IMPROVE OUTCOMES (THE ACCESS TRIAL) | |||||||||||||
Medical condition: Attenuation of the high inflammatory burden in Community-Aquired Pneumonia (CAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004323-37 | Sponsor Protocol Number: PEARL-trial | Start Date*: 2019-06-06 | ||||||||||||||||||||||||||
Sponsor Name:Academic Medical Centre | ||||||||||||||||||||||||||||
Full Title: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-c... | ||||||||||||||||||||||||||||
Medical condition: post-TIPS Hepatic Encephalopathy (HE) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002089-11 | Sponsor Protocol Number: CMBG453B12301 | Start Date*: 2020-06-23 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla... | ||||||||||||||||||
Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005778-11 | Sponsor Protocol Number: NP031112-08B03 | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:Noscira S.A. | |||||||||||||
Full Title: A 14 week double-blind, placebo-controlled, randomized, escalating dose study to evaluate the safety and tolerability of three oral doses of NP031112, a novel GSK3 inhibitor, in mild to moderate Al... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000270-57 | Sponsor Protocol Number: GRC4039-204 | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:Glenmark Pharmaceuticals SA | |||||||||||||
Full Title: A phase II, 12-week randomized, double-blind, triple dummy, parallel group, placebo-controlled, dose range finding study to evaluate safety, tolerability and efficacy of revamilast in patients wit... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001455-39 | Sponsor Protocol Number: OPN-305-102 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanis... | |||||||||||||
Medical condition: Prevention of Kidney Graft Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002322-85 | Sponsor Protocol Number: KAN0006 | Start Date*: 2020-07-02 |
Sponsor Name:Kancera AB | ||
Full Title: KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics. | ||
Medical condition: Acute respiratory distress syndrome (ARDS) in COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000661-23 | Sponsor Protocol Number: NEPHSTROM | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri | ||||||||||||||||||
Full Title: NOVEL STROMAL CELL THERAPY FOR DIABETIC KIDNEY DISEASE (NEPHSTROM Study) | ||||||||||||||||||
Medical condition: Patients with type 2 diabetes and clinically-diagnosed progressive diabetic kidney disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001387-20 | Sponsor Protocol Number: ELA026-CP002 | Start Date*: 2021-10-11 | ||||||||||||||||
Sponsor Name:Electra Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymph... | ||||||||||||||||||
Medical condition: sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients r... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000200-10 | Sponsor Protocol Number: GFM-DAC-CMML | Start Date*: 2014-08-12 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies (GFM) | |||||||||||||
Full Title: A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001836-44 | Sponsor Protocol Number: UCL/11/0119 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | |||||||||||||
Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006254-85 | Sponsor Protocol Number: CeTMad/ELA/2011 | Start Date*: 2013-02-08 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three d... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
